MD Anderson Cancer Center at Cooper — Camden, New Jersey

Public research footprint of MD Anderson Cancer Center at Cooper, compiled from the ClinicalTrials.gov public registry.

105

Registered studies

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma · Stage IVA Cervical Cancer AJCC v6 and v7 · Breast Cancer · Resectable Pancreatic Acinar Cell Carcinoma

Recently updated registry entries

NCT03907488 — Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in… (Active Not Recruiting)
NCT07059845 — A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment… (Recruiting)
NCT01274338 — Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage… (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at MD Anderson Cancer Center at Cooper?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 04, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.